The antianginal effect of molsidomine in prolonged oral therapy. A double blind, crossover, randomized study.
A double blind, crossover, random assignment study was undertaken in two 1-monthly stages following aw one-week wash-our period. Cyclo-ergometric tests were used to evaluate the antianginal effects of molsidomine compared with a placebo administered to 5 ambulatory patients with stable angina pectoris. After oral molsidomine (3 x 2 mg/day) the improvement of the evaluated parameters was significant: maximal exercise capacity, total workload, S-T segment depression. The therapeutic superiority of molsidomine compared to placebo is statistically significant. The effectiveness and tolerance observed in this clinical trial confirm the conclusions of numerous investigators.